A placebo-controlled randomized clinical trial was conducted in six centres to compare the effects of a 14 day treatment with either SO \lg ethinyl oestradiol daily or 2.5 mg oestrone sulphate daily, on depot medroxyprogesterone acetate (DMPA)-induced prolonged bleeding. Out of 1035 women admitted to the study, 278 requested treatment and were given ethinyl oestradiol (n = 90), oestrone sulphate (n = 91) or placebo (n = 97). Ethinyl oestradiol was successful in stopping the bleeding episode in 93% of cases, compared with oestrone sulphate and placebo which had success rates of 76 and 74% respectively. However, the relative advantage of ethinyl oestradiol was marginal, with an average reduction of 1 bleeding day and 3 spotting days compared with the other two groups. Immediately after treatment, women given ethinyl oestradiol had less bleeding but a more unpredictable pattern than the other two groups. In the long term, there were no differences between the bleeding patterns or the discontinuation rates for any reason in the three groups, and the most important single reason for discontinuation in those groups remained 'menstrual problems'. In summary, the study showed that treatment of DMPA-induced prolonged bleeding with ethinyl oestradiol had a limited short-term effect but no beneficial effect on the acceptability of DMPA as a contraceptive method. Treatment with oestrone sulphate was no different from placebo.
Introduction
Depot medroxyprogesterone (DMPA) given at a dose of 150 mg every 3 months is a highly effective method of contraception used by -10 million women world wide (United Nations Population Fund, 1994) . However, like other progestogenonly methods, it induces marked disturbances in the vaginal bleeding pattern which greatly affect its acceptability. In a comparative analysis of vaginal bleeding patterns induced by different hormonal contraceptive methods (Fraser, 1994) , bleeding induced by DMPA was found to be the most unpredictable, with marked variations between individuals and even within individuals. During the first 3 months, 65% of the users experience irregular or prolonged bleeding and 10% develop amenorrhoea. At the end of the first year of use, the incidence of amenorrhoea is 40%, while 30% of users still experience irregular or prolonged bleeding, indicating that there is limited overall improvement in bleeding patterns with time.
The mechanisms of menstrual bleeding and how they are affected by progestogens are poorly understood. Thus the treatments offered to progestogen users with vaginal bleeding disorders are mostly empirical. This lack of basic understanding is reflected in the wide range of therapies used in practice by clinicians (Fraser, 1983) . In addition, there have been few randomized placebo-controlled clinical trials comparing the effectiveness of different treatments. One exception is the comparative evaluation of ethinyl oestradiol, levonorgestrel and ibuprofen in Norplant users with prolonged bleeding (Diaz et al., 1990) , which suggested a beneficial effect of oestrogens on vaginal bleeding. A similar placebo-controlled study has not been carried out in DMPA users.
The purpose of our study was to assess the short-and long-term therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding lasting >7 days occurring in women using DMPA for contraception.
Materials and methods

Clinical trial procedures
This study was conducted in six centres in Alexandria (Egypt), Bangkok (Thailand), Chiang Mai (Thailand), Jakarta (Indonesia), Karachi (Pakistan) and Manila (Philippines). Women were eligible for enrolment in the study if they were aged between 18 and 40 years, attended the family planning clinic for contraception and were willing to start using 150 mg DMPA every 3 months. Those admitted to the study were asked to keep a menstrual diary for 18 months. Subjects who had a vaginal bleeding episode lasting >7 days during their first or second injection interval, and who wished to be treated, were given a 14 day course of 50 (xg ethinyl oestradiol daily, 2.5 mg piperazine oestrone sulphate daily or placebo, assigned at random and administered in a double-blind fashion. Treated subjects returned to the clinic at the end of the 14 day treatment period. If the vaginal bleeding had stopped for >2 days during this period and had not recurred, this was considered to be a short-term therapeutic success. If the treatment had failed, the investigator was free to give the subject a second treatment of his/her choice. The long-term effects were evaluated over a 12 month follow-up period using the women's menstrual diary records.
Investigators were asked to exclude from recruitment women who: were pregnant or had been lactating during the past 6 months; had diabetes, a history of thromboembolism, confirmed hypertension, recent or severe liver disease, a Papanicolaou smear grade 3 or higher, vaginal bleeding of unknown aetiology, abnormal discharge from the nipples or any known or suspected malignancy; were using barbiturates, anti-convulsants, rifampicin, systemic corticosteroids, drugs affecting the cardiovascular or hepatic systems, or any drug used on a long-term basis; or had used oral contraceptives within the last 6 months or any injectable contraceptive preparation within the previous 12 months.
Statistical methods
The reference period method, proposed originally by Rodriguez et al. (1976) , and developed further in the Special Programme of Research, Development and Research Training in Human Reproduction (Belsey et aL, 1986) , was used to analyse the menstrual diary records. A bleeding/spotting episode was defined as any set of *1 bleeding/ spotting days, bounded at each end by 2=2 bleedingfree days, where a bleeding-free day is one on which neither bleeding nor spotting is recorded. A bleeding-free interval was defined as any set of s*2 consecutive bleeding-free days, bounded at each end by bleeding or spotting days. Thus, a single bleeding-free day was treated as part of the episode surrounding it.
The following bleeding pattern indices were calculated for each woman for each 90 day reference period: (i) the number of bleeding/spotting days; (ii) the number of bleeding/spotting episodes; (iii) the mean, maximum and range of bleeding/ spotting episode lengths; and (iv) the mean and range of bleeding-free interval lengths.
Only diaries that had been completed for at least 60 days in a reference period were included in the analysis. If the diary had been completed for at least 60 but <90 days, the numbers of bleeding/ spotting days and bleeding/spotting episodes were adjusted to the 90 day reference period by dividing by the number of completed days in the diary and multiplying by 90. The lengths of episodes and intervals were not truncated, even if they overlapped two or more reference periods. By definition, the range of interval lengths could only be calculated if the woman had two or more intervals start during the period.
The first and the last event of the entire diary are incomplete. Because their true length is unknown, they were excluded from the calculation of the minimum length. However, their length was used in the calculation of the maximum when it was found greater than the longest event in the reference period.
The numbers and proportions of women with clinically important bleeding patterns in a 90 day reference period were determined according to the following definitions: (i) amenorrhoea, no bleeding throughout the reference period; (ii) infrequent bleeding, less than two bleeding/spotting episodes; (iii) frequent bleeding, more than four bleeding/ spotting episodes; (iv) irregular bleeding, a range of lengths of bleeding-free intervals >17 days; (v) prolonged bleeding, at least one bleeding/spotting episode lasting 5*10 days. These definitions were derived, as closely as possible, from the 5th or 95th percentile of the distribution of the corresponding bleeding pattern index in a group of untreated women. With these definitions, amenorrhoea, infrequent bleeding and frequent bleeding were mutually exclusive, whereas possible combinations occurred with prolonged bleeding and irregular bleeding. Conversely, patterns were considered normal or acceptable if, in a 90 day reference period, they included two, three or four bleeding/ spotting episodes, none lasting >9 days and had a range of lengths of bleeding-free intervals <18 days.
An event, whether an episode or an interval, was counted in die reference period in which it began. Thus a reference period is 'eventless' if an event starts before and stops after the 90 days being considered. In the case of a continuous interval, the pattern was classified as 'amenorrhoea'; in the case of a continuous bleeding/ spotting episode, the pattern was classified as 'prolonged and infrequent' because diere were less tiian two distinct bleeding/spotting episodes beginning in the reference period.
Results
Enrolment of subjects
A total of 1035 women were recruited into the study, including 199 in Alexandria (Egypt), 200 in Bangkok (Thailand), 104 in Chiang Mai (Thailand), 200 in Jakarta (Indonesia), 200 in Karachi (Pakistan) and 132 in Manila (Philippines). A total of 297 women had protocol violations: 34 women had their first injection beyond day 5 of their menstrual cycle, 260 women had been pregnant within the last 6 months, two women had used oral contraceptives within the last 6 months, and one woman had hypertension on admission. However, all of these women were included in the analysis.
Of the 260 women who had been pregnant within 6 months of admission, 210 had had their delivery or abortion at least 2 months prior to admission, and 16 women had delivered within 17 days of admission (their menstrual records are described in more detail below).
Subject characteristics at admission
Subject characteristics at admission in each of the centres and at all centres combined are shown in Table I . The mean age of the women was 27 years and, on average, their last pregnancy had ended 2 years prior to admission. Of the subjects, 50% had used some form of contraception previously, and had stopped their last contraceptive method an average of 3.5 mondis before admission. Half of diem had used an intrauterine device as their last contraceptive method. There were significant differences in all the subject characteristics between centres.
Women experiencing an episode of prolonged bleeding while using DMPA
Of the 1035 women in the study, 456 (44%) experienced a bleeding/spotting episode lasting >7 days during the first 6 months of DMPA use. Of those, only 278 (61%) presented for treatment. In addition, there were marked differences within centres (Table H) : the percentage of women experiencing an episode of prolonged bleeding ranged from 20% in Jakarta to 77% in Manila. The percentage of those women presenting for treatment ranged from 24% in Karachi to 86% in Chiang Mai. Of the 278 women randomized to treatment, 90, 91 and 97 were given ethinyl oestradiol, oestrone sulphate and placebo respectively. Their distribution by centre is shown in Table II . In total, they represented 27% of the study population, but the percentage of women in each centre varied from 13% in Karachi to 55% in Manila.
The subject characteristics of different groups are shown in Table HI . The groups include: (i) women who experienced a bleeding/spotting episode longer than 7 days in the first 6 months of DMPA use and were treated with ethinyl oestradiol; (ii) women who experienced a bleeding/ UPB = untreated, with one bleeding/spotting episode >7 days long; U •» untreated, without one bleeding/spotting episode >7 days long. 'Significant difference between women wbo did not experience prolonged bleeding and all other groups (P < 0.05), and between treated women and untreated women with one episode of prolonged bleeding/spotting (P < 0.01). ''Ever users only. Significant difference between women who did not experience prolonged bleeding and all other groups (P < 0.001), and between treated and untreated women with one episode of prolonged bleeding/spotting (P < 0.01).
spotting episode longer than 7 days in the first 6 months of DMPA use and were treated with oestrone sulphate; (iii) women who experienced a bleeding/spotting episode longer than 7 days in the first 6 months of DMPA use and were treated with placebo; (iv) women who experienced a bleeding/ spotting episode longer than 7 days in the first 6 months of DMPA use but did not attend for treatment (coded UPB); and (v) women who did not have a bleeding/spotting episode longer than 7 days in the first 6 months of DMPA use (coded U).
There was no difference in age, weight or height between the groups. Women who did not experience a single bleeding/spotting episode longer than 7 days in the first 6 months of DMPA use differed from other groups in that their pregnancy had ended a longer time before admission (P < 0.05), and, for those who had used contraception in the past, they had stopped their last contraceptive method earlier (P < 0.001), although there was no difference in the type of contraception they last used.
Among the women who experienced at least one bleeding/spotting episode longer than 7 days, those who did not attend for treatment differed from those who were treated in that their pregnancy had ended more recently (P < 0.01), and those who had used contraception before had discontinued their last method of contraception earlier (P < 0.01). . The menstrual diaries of the different groups of women, recorded during the first reference period of 90 days or until treatment started, were compared (Figure 1 ). Only one-third of the women who received treatment were included in this analysis because of the necessity to exclude diaries with <60 days completed. Women who had a bleeding/ spotting episode longer than 7 days but did not attend for treatment differed from those who were treated: they had a similar number of bleeding/ spotting days and bleeding/spotting episodes, similar ranges of lengths of bleeding/spotting but a greater range of lengths of bleeding-free intervals (P < 0.001). The analysis of the clinically import- ant patterns (data not shown) confirmed that these women tended to have more 'prolonged' and more 'irregular' patterns. The women who had been enrolled soon after delivery were all from Chiang Mai. Their diaries were analysed separately and compared with those of other Chiang Mai women. No difference was found between the bleeding patterns of the 16 women who were admitted within 17 days of delivery and those of the 77 women who were admitted at least 2 months after delivery. In particular, there was no evidence that women who were given DMPA shortly after delivery experienced more 'prolonged' bleeding.
Randomization to treatment: treatment initiation
There were no significant differences between the subjects randomized to the three treatment groups in terms of age, weight, height, time since the last pregnancy ended, time since the last contraceptive method was used or type of method last used (Table HI) .
There was no difference in the length of time from the first DMPA injection to the beginning of treatment between the three groups. The median time was 43 days among women treated with ethinyl oestradiol, 44 days among women treated with oestrone sulphate and 47 days among women treated with placebo. One-third of the women in each group were treated in the first 30 days of method use, and >80% were treated within the first 90 days. Although the time to treatment varied between centres, from a median of 30 days in Bangkok to 63 days in Karachi, the difference was not statistically significant
Effect of treatment during the period of pill-taking
Using the definition of success mentioned in Materials and methods, treatment was more successful in the short term for the women treated with ethinyl oestradiol (93%) than among those given oestrone sulphate (76%) or placebo (74%) (P < 0.001) ( Table IV) . The success rate for women treated with ethinyl oestradiol or oestrone sulphate did not differ significantly among the centres, but the success rate did vary significantly among the centres for women treated with placebo (P < 0.05). The time to cessation of bleeding varied with each treatment, as illustrated in Figure 2 . The median time to cessation of bleeding/spotting was 5, 9 and 10 days for the women treated with ethinyl oestradiol, oestrone sulphate and placebo respectively.
The number of bleeding/spotting days experienced during treatment also varied with treatment ( Figure 3) . The median number of bleeding/spotting days was 5, 9 and 9 days for the women treated with ethinyl oestradiol, oestrone sulphate and placebo respectively. However, when bleeding days only were counted, the median number of bleeding days experienced during the period of treatment was 2, 2 and 3 for the ethinyl oestradiol, oestrone sulphate and placebo groups respectively.
Of the 56 women in whom treatment failed, 11 received no further treatment The most common second treatment, given to 15 women, was a combined oral contraceptive containing levonorgestrel and 50 |ig ethinyl oestradiol. Other treatments included oestradiol cypionate (n = 6), conjugated oestrogens (n = 2), haemostatic agents (n = 4) and non-steroidal anti-inflammatory drugs (n = 4); 14 women received iron, vitamins, calcium and/or diazepam.
Mid-term effect of treatment
The bleeding patterns experienced by each group were compared before treatment and during the 3 months following. Although the diaries of the same women were being compared before and after treatment, only 31-32 per group were available for analysis before treatment compared with 71-73 per group after treatment, because of the need to have a diary with at least 60 days completed for analysis. The distributions of these indices are shown as box-whisker plots in with oestrone sulphate or placebo) had less bleeding/spotting days and slightly more but shorter bleeding/spotting episodes after treatment. Comparisons between the three treatment groups showed that after treatment the ethinyl oestradiol group had less bleeding/spotting days than the oestrone sulphate (P < 0.01) and placebo (P < 0.01) groups. In all three groups, the bleeding/ spotting-free intervals were longer and more variable in length after treatment, and the variability was greatest in the ethinyl oestradiol group. The clinically important patterns experienced by the three groups of women did not differ significantly before treatment Likewise, there were no significant differences between the three groups after treatment (data not shown). Before treatment, the incidence of 'prolonged' bleeding varied between 34 and 47%, and that of 'irregular' bleeding between 28 and 50%. With treatment, the most important changes were observed in these patterns, with 'prolonged' bleeding experienced by 22-31% of women and 'irregular' bleeding by 59-71% of women.
Long-term follow-up
A comparison was made of the menstrual diaries of the five groups of subjects mentioned above over the third to sixth injection intervals (i.e. 6-18 months after the start of DMPA use). For this analysis, the indices were calculated over six 90 day reference periods, starting with the day on which the woman received her third DMPA injection. The distribution of 'clinically important patterns' is illustrated in Figure 5 .
Throughout the period of follow-up, the untreated group (U) had a bleeding pattern significantly different from those of the other groups. These women continued to have less bleeding/ spotting days, less bleeding/spotting episodes, shorter bleeding/spotting episodes and longer bleeding/spotting-free intervals than any of the other groups. In terms of patterns, they had more 'amenorrhoea' and less 'prolonged', less 'frequent' and less 'irregular' patterns than the other groups.
Among those who had at least one bleeding/ spotting episode longer than 7 days during the first two injection intervals, those who did not attend for treatment generally had less bleeding/spotting days and less bleeding/spotting episodes than those who were treated. In the third reference period, they also had longer bleeding/spotting episodes and longer bleeding/spotting-free intervals. In terms of patterns, they had less 'frequent' and less 'irregular' patterns and more 'amenorrhoea'.
Among the three treated groups, there were very few differences during the period of follow-up. In the third reference period, the placebo-treated group had longer bleeding/spotting episodes and shorter bleeding/spotting-free intervals.
Discontinuation reasons: relationship with bleeding patterns
The 1 year life-table discontinuation rates for each of the five groups are shown on Table V . A graphical representation of these rates for different reasons over time is given in Figure 6 . There was no significant difference between the discontinuation rates of the three treated groups for any reason. The most important single reason for discontinuation was 'bleeding problem' with 1 year rates of 25, 17 and 17% for the ethinyl oestradiol, oestrone sulphate and placebo groups respectively. The overall discontinuation rates at 1 year were 44, 41 and 41% for the three groups respectively.
The 'UPB' group (women who were eligible for treatment but chose not to attend) had similar 1 year discontinuation rates to the three treated groups. The only significant difference was a higher 1 year discontinuation rate for 'other medical reasons' of 7% in the 'UPB' group compared with 0-2% in the treated groups. Other medical reasons in the 'UPB' group included a variety of reasons represented by one case each, except for weight gain (three cases).
The 1 year discontinuation rates for the untreated group were lower than in any other group for most reasons. Significant differences were found between the rates of the five groups for 'all menstrual problems' (P < 0.001), 'other medical reasons' (P < 0.001), 'all medical reasons' (P < 0.001), 'personal reasons' (P < 0.05) and all reasons taken together (P < 0.001). The discontinuation rate for amenorrhoea was no greater in this group than in any of the other groups. 
Discussion
In this clinical trial, women had to have experienced a vaginal bleeding episode lasting at least 7 days during the first 6 months of DMPA use to be eligible for treatmenL These represented between 20 (as in Jakarta) and 77% (as in Manila) of the study population in different centres. Such variations in the bleeding patterns of DMPA users between different centres have been observed in previous clinical trials. In fact, in an analysis of menstrual diaries collected from women using different hormonal methods of contraception in a variety of centres world wide, bleeding patterns were more closely related to the woman's geographical region of residence than to any other demographic variable. Such regional variations were particularly marked among women using DMPA (Belsey et aL, 1988a) . A number of factors can account for such findings, including differences in the pharmacokinetics of DMPA in different populations which have been well documented (Garza-Flores et al., 1994) .
Of those who were eligible for treatment, a variable proportion, ranging from 24% in Karachi to 86% in Chiang Mai, presented for treatment. There again, a number of factors were at play to explain these differences between centres, which included the tolerance towards vaginal bleeding disturbances, the counselling offered and the conduct of the study, as well as the bleeding pattern itself. Indeed, it is noticeable that the women who chose not to have treatment in fact had longer episodes but also a greater range of durations of bleeding-free intervals, suggesting that long intervals made the episodes of prolonged bleeding more tolerable. Furthermore, tolerance has sociocultural, religious and psychological components, and previous studies have illustrated how similar bleeding patterns can translate into very different continuation rates in different centres (World Health Organization, 1987) .
In a previous analysis of menstrual diaries collected from DMPA users (Belsey et al, 1988b) , more obese women were found to have fewer bleeding/spotting days and episodes than slimmer women, and also tended to have shorter episodes and longer intervals. However, in this study, no correlation was found between the bleeding patterns and the age, weight or height of the subjects.
There was no difference in the bleeding patterns or in the discontinuation rates between the women treated with oestrone sulphate and those who were given placebo tablets throughout the 18 months of the clinical trial. Women who took ethinyl oestradiol had an effect of treatment because, on average, their bleeding episode was shortened by 1 bleeding day and 3 spotting days. During the 3 months that followed treatment, they experienced less bleeding/ spotting days, had shorter but slightly more frequent bleeding/spotting episodes and had a greater range of lengths of bleeding/spotting-free intervals, indicating that their bleeding pattern was more unpredictable. Beyond 3 months, there were no differences between the vaginal bleeding patterns of the three treatment groups. Thus the benefit of treatment with ethinyl oestradiol was marginal and short lived. The difference of effect between oestrone sulphate and ethinyl oestradiol reflects the relative potency of these oestrogens. However, even ethinyl oestradiol is not very effective, possibly because of the suppressive effect of DMPA on endometrial oestrogen receptors (Tseng and Gurpide, 1975) which limits the potential efficacy of oestrogen therapy. Endometrial proliferation is also inhibited by DMPA and, as early as 1 month after the first injection, the endometrium is thin and atrophic. It would appear that the limited capacity of ethinyl oestradiol to promote endometrial tissue growth leads to the erratic bleeding pattern observed in this study. Thus it is unclear whether a longer treatment period would have offered more benefit to these women because it might have led to a more unpredictable bleeding pattern, more difficult to tolerate.
In conclusion, these results challenge the practice of using oestrogens in the treatment of DMPAinduced bleeding. Although ethinyl oestradiol may be effective in stopping an episode of prolonged bleeding, it leads subsequently to a more unpredictable vaginal bleeding pattern and does not improve the acceptability of this method of contraception. Further research is needed for a greater understanding of the mechanisms of vaginal bleeding so that appropriate treatments can be defined for progestogen-induced prolonged bleeding and new contraceptive methods can be developed which are free from this side-effect.
